Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2007 / Cilt: 41 - Sayı: 4

A new alternative in the treatment of hand eczama: topical pimecrolimus

El ekzaması tedavisinde yeni bir seçenek: topikal pimekrolimus

Pages
125–128
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: It is concluded that topical pimecrolimus cream appears to be an effective and easily appliable treatment alternative for all manifestations of hand eczema except for vesiculation, without any rebound and tachyphylaxis. (Turkderm 2007; 41: 125-8)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hand eczema is the most common form of occupational dermatoses.
📊
Key Findings & Data:In this study, we aimed to evaluate the efficacy of pimecrolimus 1% cream, an ascomisin derivative successfully used for atopic dermatitis, in the treatment of hand eczema.
💡
Conclusion & Impact:Conclusion: It is concluded that topical pimecrolimus cream appears to be an effective and easily appliable treatment alternative for all manifestations of hand eczema except for vesiculation, without any rebound and tachyphylaxis. (Turkderm 2007; 41: 125-8)
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

Hand eczema is the most common form of occupational dermatoses. Because of chronic and relapsing course, therapy is a problem for both physician and patient. New treatment alternatives have been investigated because of side effects of long-term topical corticosteroids use. In this study, we aimed to evaluate the efficacy of pimecrolimus 1% cream, an ascomisin derivative successfully used for atopic dermatitis, in the treatment of hand eczema. Material and Method: In this placebo-controlled, randomized study, pimecrolimus 1% cream was applied on one hand and placebo on the other hand of 25 patients twice daily for 8 weeks. Response to the therapy was assessed clinically at 2., 4., 6. and 8. weeks of the therapy. In the clinical assessment, erythema, desquamation, lichenification, edema, vesiculation and fissuring were scored between 0-4. Same scoring system was used also for the pruritus symptom of the patients. Side effects during the therapy were also recorded. The patients were followed for 8 additional weeks after the end of the therapy. Results: Nine male and 15 female patients with ages ranging from 18 to 63 (mean 35.79) completed the study. Of the patients, 14 were housewives, 4 were health workers, 3 were teachers, 1 was policeman, 1 was farmer and 1 was a haberdasher. The duration of disease ranged between 6 months and 20 years (mean 4.9 years). Diagnosis of irritant contact dermatitis was made in 13 patients and allergic contact dermatitis in 11 patients. Pimecrolimus 1% cream was well tolerated in all patients and no side effect was observed. The clinical score of pimecrolimus-applied hand improved significantly when compared with placebo applied hand (p=0.04). Conclusion: It is concluded that topical pimecrolimus cream appears to be an effective and easily appliable treatment alternative for all manifestations of hand eczema except for vesiculation, without any rebound and tachyphylaxis. (Turkderm 2007; 41: 125-8)

Özet

Meslek dermatozlar› aras›nda en s›k görülen tablo el ekzemalar›d›r. El ekzemalar›n›n kronik ve tekrarlay›c› seyrinden dolay› tedavisi hem hasta hem de hekim için sorun teflkil etmektedir. Topikal kortikosteroidlerin uzun süreli kullan›mlar›na ba¤l› yan etkilerinden dolay› yeni tedavi aray›fllar› do¤mufltur. Bu çal›flmam›zda askomisin türevi olan ve atopik dermatit tedavisinde güvenle kullan›lan topikal pimekrolimus %1 kremin el ekzemas› tedavisindeki etkinli¤ini de¤erlendirmeyi amaçlad›k. Gereç ve Yöntem: Plasebo kontrollü, randomize çal›flmam›zda bilateral el ekzemas› olan toplam 25 hastan›n her bir eline plasebo ve di¤er taraf›na pimekrolimus %1 krem uygulat›ld›. Çal›flman›n 2., 4., 6. ve 8. haftalar›nda tedaviye cevap klinik olarak de¤erlendirildi. Klinik de¤erlendirmede eritem, deskuamasyon, likenifikasyon, ödem, vezikülasyon, fissür oluflumu 0-4 aras›nda skorland›. Ayr›ca hastalar›n kafl›nt› de¤erlendirmesinde ayn› skorlama kullan›ld›. Tedavi s›ras›nda görülen yan etkiler de kay›t edildi. Hastalar 8 haftal›k tedavi dönemini takiben yaklafl›k 8 hafta süresince tedavisiz izlendi. Bulgular: Tedaviyi tamamlayan 9 erkek, 15 kad›n hastan›n yafllar› 18 - 63 aras›nda (ortalama yafl 35.79) de¤ifliyordu. Meslek gruplar› incelendi¤inde 14’ü ev han›m›, 4’ü sa¤l›k personeli, 3’ü ö¤retmen, 1’i polis, 1’i çiftçi ve 1’i tuhafiye malzemeleri imalatç›s› olarak de¤ifliyordu. Hastal›k süreleri 6 ay-20 y›l (ortalama 4.9 y›l) aras›nda idi. On üç hastada iritan kontakt dermatit, 11 hastada allerjik kontakt dermatit tan›s› saptand›. Pimekrolimus %1 krem hastalar taraf›ndan iyi tolere edilmifl ve hiçbir yan etki gözlenmemifltir. Tedavi sonu ilaç uygulanan ele ait toplam klinik skorlar plasebo uygulanan ele ait skorlar ile karfl›laflt›r›ld›¤›nda anlaml› bir azalma saptanm›flt›r (p=0.04). Sonuç: Sonuç olarak el ekzemalar›n›n tedavisinde topikal pimekrolimusun vezikülasyon d›fl›ndaki tüm belirtileri bask›lamada oldukça etkili, ribaund ve tafliflaksiye neden olmayan, kullan›m› kolay bir tedavi seçene¤i olabilece¤i sonucuna var›lm›flt›r. (Türkderm 2007; 41: 125-8)

🔖

Cite This Article

BAŞKAN, B. E., TUNALI, Ş., KAÇAR, D. S., TURAN, A. (2022). A new alternative in the treatment of hand eczama: topical pimecrolimus. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 41 - Sayı: 4, 125–128. https://ajindex.com/articles/622138

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Rycroft RJG: Occupational dermatoses. In: Champion RH, Burton JL, Burns DA, Ebling FJG (eds). Textbook of Dermatology. Alt›nc› Bask›. Blackwell-Science:London; 1998:861-882
  2. Elston DM, Ahmet DDF, Watsky KL, Schwarzenberger K: Hand dermatitis. J Am Acad Dermatol 2002; 47:291-299
  3. Meding B: Epidemiology of hand eczema in an industrial city. Acta Derm Venereol 1990;153:1-43
  4. Coenraads PJ, Nater JP: Sickness and absence from work due to skin diseases in the construction industry. Review of literature. Derm Beruf Umwelt 1984;32:17-21
  5. Adiesh A, Meyer JD, Cherry NM: Prognosis and work absence due to occupational contact dermatitis. Contact Dermatitis 2002;46:273-279
  6. Halkier-Sorensen L: Occupational skin diseases. Contact Dermatitis 1996;35:1-120
  7. Cvetkovski RS, Rothman KJ, Olsen J, Mathiesen B et al: Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. Br J Dermatol 2005;152:93-98
  8. Marks R: Adverse side effects from the use of topical corticosteroids. In: Maibach HI, Surger C, eds. Topical Corticosteroids. Basel. Karger 1992;170-83
  9. Queille Roussel C, Graeber M Thurston M et al: SDZ ASM 981 is the first non-steroid that suppresses established nickel-contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000;42:349-350
  10. Thaci D, Steinmeyer K, Ebelin ME, Scott G, Kaufmann R: Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated,safe and effective.An open study. Dermatology 2003;207:37-42
  11. Belsito DV, Fowler JF Jr, Marks JG Jr, et al: Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004;73:31-38
  12. Gupta AK, Chow M: Pimecrolimus. A review. J Eur Acad Dermatol Venereol 2003:17: 493-503
  13. Grassberger M, Baumruker T, Enz A et al: A novel anti-inflammatory drug SDZ ASM 981 for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:263-273
  14. Özkaya-Bayaz›t E, Özarma¤an G: Mesle¤e ba¤l› el ekzemalar›nda medikal ve hukuksal yaklafl›m. Turkderm 1998;8-28
  15. Schurmeyer-Horst F, Luger TA, Bohm M: Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology 2007;214:99-100.